Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Metabolic Disorders

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • ID:RM0034528
  • Published: December-2016
  • Pages:356
  • GlobalData
1 of 3

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary The Author estimates sales of dyslipidemia therapeutics to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. The Author expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in the dyslipidemia market in the 7MM, reaching peak sales of $9.5B in 2025. Despite the launch of such efficacious lipid-lowering therapies, there is ample opportunity for pipeline drugs targeting the broa
Show More

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary The Author estimates sales of dyslipidemia therapeutics to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. The Author expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in the dyslipidemia market in the 7MM, reaching peak sales of $9.5B in 2025. Despite the launch of such efficacious lipid-lowering therapies, there is ample opportunity for pipeline drugs targeting the broader mixed dyslipidemia market. As pricing is expected to be the strongest barrier to uptake in the dyslipidemia space, cost-effective therapies will be more successful at penetrating the market. Highlights Key Questions Answered - The level of unmet needs in the dyslipidemia market remains high. Will the pipeline drugs fulfil these unmet needs of the market Key Opinion Leaders (KOLs) interviewed by The Author provide insights and highlight opportunities for drug developers. - The 10-year forecast period will mark the launch of several biologics targeting PCSK9. How will the market be impacted Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why - Pricing has a strong influence over drug uptake. How will reimbursement affect the adoption of combination therapy in the different markets Key Findings - The major drivers for growth across the 7MM in the dyslipidemia market during the forecast period will be the launch of the novel PCSK9 targeting therapies. - KOLs interviewed by The Author opined that ETC-1002 (bempedoic acid) will be a strong contender, and will displace ezetimibe as the standard of care for statin intolerant patients. - The highest revenue generators in the 7MM market at the end of 2025 will be the PCSK9 targeting therapies and ETC-1002. - In other interviews, KOLs highlighted that the greatest unmet need in the dyslipidemia space is disease awareness, with a large proportion of patients going underdiagnosed, and of those who are diagnosed, drug treatment rates are also low. Scope - Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. - Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the dyslipidemia therapeutics market. - Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. - Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the 7MM dyslipidemia therapeutics market from 2015-2025. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


Less

1 of 3


1 Table of Contents 1 Table of Contents 10 1.1 List of Tables 19 1.2 List of Figures 24 2 Introduction 26 2.1 Catalyst 26 2.2 Related Reports 27 3 Disease Overview 28 3.1 Etiology and Pathophysiology 28 3.1.1 Etiology 28 3.1.2 Pathophysiology 30 3.2 Symptoms 34 3.3 Prognosis 34 3.4 Quality of Life 34 4 Epidemiology 35 4.1 Disease Background 35 4.2 Risk Factors and Comorbidities 35 4.3 Global Trends 37 4.4 Forecast Methodology 37 4.4.1 Sources Used Tables 37 4.4.2 Forecast Assumptions and Methods 42 4.4.3 Sources Not Used 58 4.5 Epidemiological Forecast for Dyslipidemia (2015-2025) 59 4.5.1 Dyslipidemia 59 4.5.2 Familial Hypercholesterolemia 63 4.5.3 Increased Low-Density Lipoprotein Cholesterol 64 4.5.4 High Triglycerides 69 4.5.5 Very High Triglycerides 74 4.5.6 Low High-Density Lipoprotein Cholesterol 76 4.6 Discussion 81 4.6.1 Epidemiological Forecast Insight 81 4.6.2 Limitations of the Analysis 83 4.6.3 Strengths of the Analysis 84 5 Disease Management 85 5.1 Diagnosis and Treatment Overview 85 5.1.1 Diagnosis 85 5.1.2 Treatment Guidelines and Leading Prescribed Drugs 87 5.1.3 Clinical Practice 90 5.2 US 92 5.3 5EU 94 5.4 Japan 97 6 Competitive Assessment 99 6.1 Overview 99 6.2 Statins 102 6.2.1 Overview of drug class 102 6.2.2 Crestor (Rosuvastatin) 104 6.3 Zetia (Ezetimibe) 110 6.3.1 Overview 110 6.3.2 Efficacy 113 6.3.3 Safety 114 6.3.4 SWOT Analysis 116 6.3.5 Forecast 116 6.4 Praluent (Alirocumab) 117 6.4.1 Overview 117 6.4.2 Efficacy 120 6.4.3 Safety 122 6.4.4 SWOT Analysis 123 6.4.5 Forecast 124 6.5 Repatha (Evolocumab) 125 6.5.1 Overview 125 6.5.2 Efficacy 127 6.5.3 Safety 130 6.5.4 SWOT Analysis 131 6.5.5 Forecast 132 6.6 Vytorin (Simvastatin/Ezetimibe) 132 6.6.1 Overview 132 6.6.2 Efficacy 134 6.6.3 Safety 135 6.6.4 SWOT Analysis 135 6.6.5 Forecast 136 6.7 Kynamro (Mipomersen) 136 6.7.1 Overview 136 6.7.2 Efficacy 138 6.7.3 Safety 139 6.7.4 SWOT Analysis 141 6.7.5 Forecast 141 6.8 Juxtapid (Lomitapide) 142 6.8.1 Overview 142 6.8.2 Efficacy 144 6.8.3 Safety 146 6.8.4 SWOT Analysis 147 6.8.5 Forecast 147 6.9 Niacin/Nicotinic Acid 148 6.9.1 Overview 148 6.9.2 Efficacy 150 6.9.3 Safety 152 6.9.4 SWOT Analysis 153 6.9.5 Forecast 153 6.10 Fibrates 153 6.10.1 Overview of Drug Class 153 6.10.2 Tricor/Trilipix (Fenofibrate/Fenofibric acid) 155 6.11 Omega-3 Fatty Acids 159 6.11.1 Overview 159 6.11.2 Lovaza (omega-3 acid ethyl esters) 160 6.11.3 Vascepa (Icosapent Ethyl) 163 6.11.4 Epanova (omega-3 carboxylic acids) 168 6.12 Bile Acid Sequestrants 172 6.12.1 Overview 172 6.12.2 Efficacy 174 6.12.3 Safety 174 6.12.4 SWOT Analysis 175 6.12.5 Forecast 175 7 Unmet Needs Assessment and Opportunity Analysis 176 7.1 Overview 176 7.2 Therapies that Target Lipoprotein(a) 178 7.2.1 Unmet Need 178 7.2.2 Gap Analysis 179 7.2.3 Opportunity 180 7.3 Cost-Effective Therapies for Dyslipidemia 180 7.3.1 Unmet Need 180 7.3.2 Gap Analysis 181 7.3.3 Opportunity 181 7.4 Efficacious TG-Lowering Therapies 182 7.4.1 Unmet Need 182 7.4.2 Gap Analysis 183 7.4.3 Opportunity 184 7.5 Improved Diagnosis, Patient Education, and Long-Term Compliance 185 7.5.1 Unmet Need 185 7.5.2 Gap Analysis 187 7.5.3 Opportunity 188 7.6 HoFH Therapies with Reduced Side Effects 189 7.6.1 Unmet Need 189 7.6.2 Gap Analysis 190 7.6.3 Opportunity 191 7.7 Therapies that Prevent or Reverse the Buildup of Atherosclerotic Plaque 191 7.7.1 Unmet Need 191 7.7.2 Gap Analysis 192 7.7.3 Opportunity 193 8 Pipeline Assessment 194 8.1 Overview 194 8.2 Promising Drugs in Clinical Development 195 8.2.1 LY3015014 197 8.2.2 Anacetrapib 202 8.2.3 AMG-899 (TA-8995/DEZ-001) 210 8.2.4 Bempedoic Acid (ETC-1002) 216 8.2.5 Volanesorsen 223 8.2.6 CER-001 228 8.2.7 ALN-PCSsc 233 8.2.8 Gemcabene 238 8.2.9 Pemafibrate (K-877) 243 8.3 Other Drugs in Development 248 9 Current and Future Players 250 9.1 Overview 250 9.2 Trends in Corporate Strategy 253 9.3 Company Profiles 255 9.3.1 AbbVie 255 9.3.2 Aegerion Pharmaceuticals, Inc. 257 9.3.3 Akcea Therapeutics, Inc. and Ionis Pharmaceuticals 258 9.3.4 Amarin 260 9.3.5 Amgen 262 9.3.6 AstraZeneca 263 9.3.7 Cerenis Therapeutics, Inc. 265 9.3.8 Daiichi Sankyo 266 9.3.9 Eli Lilly 267 9.3.10 Esperion Therapeutics, Inc. 269 9.3.11 Genzyme 270 9.3.12 Merck & Co. 272 9.3.13 Regeneron Pharmaceuticals, Inc. 274 9.3.14 Sanofi 275 9.3.15 The Medicines Company 277 10 Market Outlook 280 10.1 Global Markets 280 10.1.1 Forecast 280 10.1.2 Drivers and Barriers - Global Issues 285 10.2 US 290 10.2.1 Forecast 290 10.2.2 Key Events 293 10.2.3 Drivers and Barriers 294 10.3 5EU 296 10.3.1 Forecast 296 10.3.2 Key Events 298 10.3.3 Drivers and Barriers 299 10.4 Japan 302 10.4.1 Forecast 302 10.4.2 Key Events 304 10.4.3 Drivers and Barriers 305 11 Appendix 308 11.1 Bibliography 308 11.2 Abbreviations 332 11.3 Methodology 338 11.4 Forecasting Methodology 338 11.4.1 Diagnosed Dyslipidemia Patients 338 11.4.2 Percent Drug-Treated Patients 339 11.4.3 Drugs Included in Each Therapeutic Class 339 11.4.4 Launch and Patent Expiry Dates 340 11.4.5 General Pricing Assumptions 341 11.4.6 Individual Drug Assumptions 342 11.4.7 Generic Erosion 348 11.4.8 Pricing of Pipeline Agents 348 11.5 Primary Research - KOLs Interviewed for this Report 349 11.6 Primary Research - Prescriber Survey 351 11.7 About the Authors 352 11.7.1 Analyst 352 11.7.2 Therapy Area Director 352 11.7.3 Epidemiologist 353 11.7.4 Director of Epidemiology 353 11.7.5 Global Director of Therapy Analysis and Epidemiology 354 11.8 About The Author 355 11.9 Disclaimer 355



List Of Tables

1.1 List of Tables Table 1: Dyslipidemia: Fredrickson Classification System 28 Table 2: Risk Factors and Comorbidities for Dyslipidemia 36 Table 3: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia 38 Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH 39 Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C 40 Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG 41 Table 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C 42 Table 8: 8MM, Total Prevalent Cases of Dyslipidemia, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 60 Table 9: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 62 Table 10: 8MM, Total Prevalent Cases of Increased LDL-C, Ages 20 Years, Both Sexes, N, Selected Years, 2015-2025 65 Table 11: 8MM, Total Prevalent Cases of High TG, Ages 20 Years, Both Sexes, N, Selected Years, 2015-2025 70 Table 12: 8MM, Total Prevalent Cases of Very High TG, Ages 20 Years, Both Sexes, N, Selected Years, 2015-2025 75 Table 13: 8MM, Total Prevalent Cases of Low HDL-C, Ages 20 Years, Both Sexes, N, Selected Years 2015-2025 77 Table 14: AACE Optimal/Near-Optimal, Borderline, and High-Risk Serum Lipid Concentrations 85 Table 15: Factors Considered for Different CVD Risk Calculators 86 Table 16: Treatment Guidelines for Dyslipidemia 88 Table 17: Most Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2015 90 Table 18: Country Profile - US 93 Table 19: Market Profile - 5EU 95 Table 20: Country Profile - Japan 98 Table 21: Intensity level of commonly used statins 103 Table 22: Product Profile - Crestor (Rosuvastatin) 106 Table 23: Efficacy of Rosuvastatin - Lipid and Lipoprotein Parameters 107 Table 24: Crestor SWOT Analysis, 2015 109 Table 25: Product Profile - Zetia 112 Table 26: Efficacy of Zetia - Primary and Secondary Endpoints, IMPROVE-IT study 114 Table 27: Safety of Zetia (Ezetimibe) 115 Table 28: Drug Zetia (Ezetimibe) SWOT Analysis, 2015-2025 116 Table 29: Product Profile - Praluent 120 Table 30: Efficacy of Praluent (alirocumab) - Primary and Secondary Endpoints, ODYSSEY LONG TERM Phase III Study 121 Table 31: Safety of Praluent (alirocumab) 122 Table 32: Praluent (Alirocumab) SWOT Analysis, 2015-2025 123 Table 33: Product Profile - Repatha 127 Table 34: Pivotal Trials of Repatha (Evolocumab) 128 Table 35: Repatha (Evolocumab) SWOT Analysis, 2015-2025 131 Table 36: Product Profile - Vytorin 133 Table 37: Efficacy of Vytorin - Primary and Secondary Endpoints, VYVA study 134 Table 38: Vytorin SWOT Analysis, 2015 135 Table 39: Product Profile - Kynamro 138 Table 40: Efficacy of Kynamro - Lipid and Lipoprotein Parameters, RADICHOL 1 Phase III Study 139 Table 41: Safety of Kynamro (mipomersen) 140 Table 42: Kynamro SWOT Analysis, 2015 141 Table 43: Product Profile - Juxtapid 144 Table 44: Efficacy of Juxtapid - Lipid and Lipoprotein parameters, Phase III Study 145 Table 45: Juxtapid SWOT Analysis, 2015 147 Table 46: Product Profile - Niaspan 150 Table 47: Niacin/Nicotinic Acid SWOT Analysis, 2015 153 Table 48: Summary of the Therapeutic Properties of Fibrates* 154 Table 49: Product Profile - Tricor/Trilipix 156 Table 50: Tricor/Trilipix SWOT Analysis, 2015 158 Table 51: Product Profile - Lovaza 161 Table 52: Efficacy of Lovaza - Pivotal Studies for the Treatment of Very High TGs 162 Table 53: Lovaza SWOT Analysis, 2015 163 Table 54: Product Profile - Vascepa 165 Table 55: Efficacy of Vascepa - ANCHOR Phase III Study 166 Table 56: Vascepa SWOT Analysis, 2015 167 Table 57: Product Profile - Epanova 169 Table 58: Efficacy of Epanova - ESPRIT Phase III Study 170 Table 59: Epanova SWOT Analysis, 2015 171 Table 60: Product Profile - Welchol 173 Table 61: Efficacy of Welchol - GLOWS Study 174 Table 62: Welchol SWOT Analysis, 2015 175 Table 63: Unmet Need and Opportunity in Dyslipidemia, 2015 178 Table 64: Product Profile - LY3015014 198 Table 65: Efficacy of LY3015014 199 Table 66: LY3015014 SWOT Analysis, 2015 201 Table 67: Product Profile - Anacetrapib 205 Table 68: Efficacy of Anacetrapib - Primary and Secondary Endpoints, DEFINE study 206 Table 69: Safety of Anacetrapib - AEs and Safety Variables, DEFINE study 207 Table 70: Anacetrapib SWOT Analysis, 2015 209 Table 71: Product Profile - AMG-899 ( TA-8995/DEZ-001) 211 Table 72: Efficacy of TA-8995 - Primary Endpoints, TULIP study 213 Table 73: AMG-899 SWOT Analysis, 2015 215 Table 74: Product Profile - ETC-1002 (Bempedoic Acid) 218 Table 75: Efficacy of ETC-1002 - Lipid and lipoprotein parameters 220 Table 76: ETC-1002 SWOT Analysis, 2015 222 Table 77: Product Profile - Volanesorsen 224 Table 78: Efficacy of Volanesorsen - Lipid and Lipoprotein Levels and Glycemic Control 225 Table 79: Volanesorsen SWOT Analysis, 2015 227 Table 80: Product Profile - CER-001 229 Table 81: Efficacy of CER-001 230 Table 82: CER-001 SWOT Analysis, 2015 232 Table 83: Product Profile - ALN-PCSsc 234 Table 84: ALN-PCSsc SWOT Analysis, 2015 237 Table 85: Product Profile - Gemcabene 239 Table 86: Efficacy of Gemcabene 240 Table 87: Gemcabene SWOT Analysis, 2015 242 Table 88: Product Profile - Pemafibrate 244 Table 89: Efficacy of Pemafibrate 245 Table 90: Safety of Pemafibrate 246 Table 91: Pemafibrate SWOT Analysis, 2015 247 Table 92: Drugs in Development for Dyslipidemia, 2015 249 Table 93: Key Companies in the Dyslipidemia Market in the 7MM, 2015 252 Table 94: Abbvie s Dyslipidemia Portfolio Assessment, 2015 257 Table 95: Aegerion Pharmaceuticals Dyslipidemia Portfolio Assessment, 2015 258 Table 96: Ionis Pharmaceuticals Dyslipidemia Portfolio Assessment, 2015 260 Table 97: Amarin s Dyslipidemia Portfolio Assessment, 2015 262 Table 98: Amgen s Dyslipidemia Portfolio Assessment, 2015 263 Table 99: AstraZeneca s Dyslipidemia Portfolio Assessment, 2015 264 Table 100: Cerenis Therapeutics Dyslipidemia Portfolio Assessment, 2015 266 Table 101: Daiichi Sankyo s Dyslipidemia Portfolio Assessment, 2015 267 Table 102: Eli Lilly s Dyslipidemia Portfolio Assessment, 2015 269 Table 103: Esperion Therapeutics Dyslipidemia Portfolio Assessment, 2015 270 Table 104: Genzyme s Dyslipidemia Portfolio Assessment, 2015 272 Table 105: Merck & Co. s Dyslipidemia Portfolio Assessment, 2015 273 Table 106: Regeneron Pharmaceuticals Dyslipidemia Portfolio Assessment, 2015 275 Table 107: Sanofi s Dyslipidemia Portfolio Assessment, 2015 277 Table 108: The Medicines Company s Dyslipidemia Portfolio Assessment, 2015 279 Table 109: Dyslipidemia Market - Global Drivers and Barriers, 2015 2025 285 Table 110: Key Events Impacting Sales for Dyslipidemia in the US, 2015-2025 293 Table 111: Dyslipidemia Market - Drivers and Barriers in the US, 2015 2025 294 Table 112: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2015-2025 298 Table 113: Dyslipidemia Market - Drivers and Barriers in the 5EU, 2015 2025 299 Table 114: National Healthcare Authorities in the 5EU Nations 299 Table 115: National Public Health Initiatives in the 5EU Nations 300 Table 116: Governmental Drug Pricing Authorities in the 5EU Nations 301 Table 117: Key Events Impacting Sales for Dyslipidemia in Japan, 2015-2025 304 Table 118: Dyslipidemia Market - Drivers and Barriers in Japan, 2015 2025 305 Table 119: Key Launch Dates for Dyslipidemia 340 Table 120: Key Patent Expiry Dates for Dyslipidemia 340 Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 351



List of Figures

1.2 List of Figures Figure 1: Classification of Dyslipidemia 30 Figure 2: 8MM Total Prevalent Cases of Dyslipidemia, Ages 20 Years, Both Sexes, N, 2015-2025 61 Figure 3: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages 20 Years, Both Sexes, N, 2015-2025 63 Figure 4: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages 20 Years, N, 2015 and 2025 64 Figure 5: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages 20 Years, N, 2015 and 2025 66 Figure 6: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages 20 Years, N, 2015 67 Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages 20 Years, 2015 68 Figure 8: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages 20 Years, 2015 69 Figure 9: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages 20 Years, N, 2015-2025 71 Figure 10: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages 20 Years, N, 2015 72 Figure 11: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages 20 Years, 2015 73 Figure 12: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages 20 Years, 2015 74 Figure 13: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages 20 Years, N, 2015-2025 76 Figure 14: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages 20 Years, N, 2015-2025 78 Figure 15: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages 20 Years, N, 2015 79 Figure 16: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages 20 Years, 2015 80 Figure 17: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages 20 Years, 2015 81 Figure 18: Statin Mechanism of Action 103 Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2015-2025 197 Figure 20: ACL inhibition 217 Figure 21: Company Portfolio Gap Analysis in Dyslipidemia, 2015-2025 253 Figure 22: Global Sales for Dyslipidemia by Region, 2015 and 2025 283 Figure 23: Global Sales for Dyslipidemia by Drug Class, 2015 and 2025 284 Figure 24: Global Sales for PCSK9 targeting therapies, 2015-2025 285 Figure 25: Sales for Dyslipidemia by Drug Class in the US, 2015 and 2025 292 Figure 26: Sales for Dyslipidemia by Drug Class in the 5EU, 2015 and 2025 297 Figure 27: Sales for Dyslipidemia by Drug Class in Japan, 2015 and 2025 303


1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.